Tamar Murray
5 Papers
Tamar Murray is an academic researcher. The author has contributed to research in topics: Medicine & Outbreak. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
Ruth Hunegnaw,Anna N. Honko,Lingshu Wang,Derick Carr,Tamar Murray,Wei Shi,Lam Nguyen,Nadia Storm,Caitlyn N. M. Dulan,Kathryn E. Foulds,Krystle N. Agans,Robert W. Cross,Joan B. Geisbert,Cheng Cheng,Aurélie Ploquin,Daphne A. Stanley,Thomas W. Geisbert,Gary J. Nabel,Nancy J. Sullivan +18 more
TL;DR: In this paper , a single-shot ChAd3-MARV vaccine generated a rapid and durable immune response with an immune correlate of protection that will support advanced clinical development, with antigen-specific antibodies serving as a predictor of protection.
25
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Melinda J. Morton Hamer,Katherine V. Houser,Amelia R. Hofstetter,Ana M. Ortega-Villa,Christine A. Lee,Anne C Preston,Brooke Augustine,Charla Andrews,Galina Yamshchikov,Somia P. Hickman,Steven Schech,Jack N. Hutter,Paul T. Scott,Paige E. Waterman,Mihret F. Amare,Victor K. Kioko,Casey K. Storme,Kayvon Modjarrad,Melanie McCauley,Merlin L. Robb,Martin R. Gaudinski,Ingelise J. Gordon,LaSonji A. Holman,Alicia T. Widge,Larisa Strom,Myra Happe,Josephine H. Cox,Sandra Vazquez,Daphne A. Stanley,Tamar Murray,Caitlyn N. M. Dulan,Ruth Hunegnaw,Sandeep Narpala,Phillip A. Swanson,Manjula Basappa,Jagada Thillainathan,Marcelino Padilla,Britta Flach,Sarah O’Connell,Olga Trofymenko,Patricia Morgan,Emily E. Coates,Jason G. D. Gall,Adrian B. McDermott,Richard A. Koup,John R. Mascola,Aurélie Ploquin,Nancy J. Sullivan,Julie A Ake,Julie E. Ledgerwood,Rebecca Lampley,Brenda Larkin,Pamela Costner,H. Wilson,Mike Read +54 more
TL;DR: The first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectORED filovirus vaccines.
13
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Betty Mwesigwa,Katherine V. Houser,Amelia R Hofstetter,Ana M. Ortega-Villa,Prossy Naluyima,Francis Kiweewa,Immaculate Nakabuye,Galina Yamshchikov,Charla Andrews,Mark O'Callahan,Larisa Strom,Steven Schech,Leigh Anne Eller,Erica L Sondergaard,Paul T. Scott,Mihret F. Amare,Kayvon Modjarrad,Amir Wamala,Allan Tindikahwa,Ezra Musingye,J. Nanyondo,Martin R. Gaudinski,Ingelise J. Gordon,LaSonji A. Holman,Jamie G Saunders,Pamela Costner,Floreliz Mendoza,Myra Happe,Patricia Morgan,Sarah H. Plummer,Somia P. Hickman,Sandra Vazquez,Tamar Murray,Jamilet Cordon,Caitlyn N. M. Dulan,Ruth Mesfin Hunegnaw,Manjula Basappa,Marcelino Padilla,Supra R. Gajjala,Phillip A Swanson,Bob C. Lin,Emily E. Coates,Jason G. Gall,Adrian B. McDermott,Richard A. Koup,John R. Mascola,Aurélie Ploquin,Nancy J. Sullivan,Hannah Kibuuka,Julie A Ake,Julie E. Ledgerwood +50 more
- 01 Aug 2023
TL;DR: The cAd3-EBO S vaccine was well tolerated with no severe adverse events, and the rapid onset and durability of the vaccine-induced antibodies make this vaccine a strong candidate for emergency deployment in Sudan Ebola virus outbreaks.
12
A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure
Anna N. Honko,Ruth Mesfin Hunegnaw,Juan I. Moliva,Aurélie Ploquin,Caitlyn N. M. Dulan,Tamar Murray,Derick Carr,Kathryn E. Foulds,Joan B. Geisbert,Thomas W. Geisbert,Joshua C. Johnson,Suzanne E. Wollen-Roberts,John C. Trefry,Daphne A. Stanley,Nancy J. Sullivan +14 more
TL;DR: A single-dose of ChAd3 vaccine protected macaques from lethal challenge with Sudan virus (SUDV) by parenteral and aerosol routes of exposure and indicates that the ChAd3-SUDV vaccine is a suitable candidate for a prophylactic vaccination strategy in regions at high risk of filovirus outbreaks.
1
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
Myra Happe,Amelia R. Hofstetter,Jing Wang,Galina Yamshchikov,LaSonji A. Holman,Laura Novik,Larisa Strom,Francis Kiweewa,S. Wakabi,Monica Millard,Colleen F. Kelley,Sarah Kabbani,Srilatha Edupuganti,Allison Beck,Florence Kaltovich,Tamar Murray,Susanna Tsukerman,Derick Carr,Carl Ashman,Daphne A. Stanley,Aurélie Ploquin,Robert T. Bailer,Richard Schwartz,Fatim Cham,Allan Tindikahwa,Zonghui Hu,Ingelise J. Gordon,Nadine Rouphael,Katherine V. Houser,Emily E. Coates,Barney S. Graham,Richard A. Koup,John R. Mascola,Nancy J. Sullivan,Merlin L. Robb,Julie A Ake,Kirsten E. Lyke,Mark J. Mulligan,Julie E. Ledgerwood,Hannah Kibuuka,the Vrc 208 and RV 422 study team +40 more
TL;DR: Two phase 1/1b trials in US and Uganda demonstrate that heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic, inducing durable antibody responses and cellular immunity, with promising implications for prophylactic and outbreak settings.
1